BackMyMD Pharmaceuticals Overview

MyMD Pharmaceuticals Common Stock

Track MyMD Pharmaceuticals's common stock ($8.2K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$8190.00
↓ 72.13% YoYΔ $-21194.00 vs prior year quarter

Peer trimmed avg / median

Loading

MyMD Pharmaceuticals Common Stock History

Loading

MyMD Pharmaceuticals vs. peers: Common Stock Comparison

Loading

MyMD Pharmaceuticals Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

MyMD Pharmaceuticals (MYMD) FAQ

MyMD Pharmaceuticals (MYMD) currently reports a common stock of $8.2K as of June 2026. That compares with $29K in the prior-year period — down 72.1% year over year. Use the charts on this page to explore MyMD Pharmaceuticals's common stock history and peer comparisons.

MyMD Pharmaceuticals's common stock decreased from $29K to $8.2K — a 72.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MyMD Pharmaceuticals reported $8.2K in common stock as of June 2026. That compares with $29K in the prior-year period — down 72.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $8.2K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MyMD Pharmaceuticals, and consider following MYMD for alerts when major investors trade the stock.

MyMD Pharmaceuticals is classified in the Healthcare sector. On common stock, it currently shows $8.2K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MYMD with unrelated industries.